PCSK9 can bind and accelerate the lysosomal degradation of low density lipoprotein receptor (LDLR) on the cell surface, thereby inhibiting the uptake of LDL‐C by liver cells, resulting in the increase of LDL‐C in plasma and accelerating the progression of atherosclerosis.11 Here, LDLR is linked to atherosclerosis.